Max Higgins, Consultant, Author at EverGlade Consulting - Page 2 of 2

Max Higgins, Consultant

Max Higgins, Consultant
MTEC RPP military medical needs

Medical Technology Enterprise Consortium (MTEC) Multi-Topic Request for Proposals

Leave a Comment / EverGlade Insights, MTEC / By

MTEC-FY-2025-Multi-Topic-Pre-Announcement Overview of Solicitation The Medical Technology Enterprise Consortium (MTEC) has released an exciting pre-announcement for its 2025 Multi-Topic Request for Proposals (RPP). This RPP calls for innovative medical prototypes addressing a range of focus areas critical to supporting military operations and improving healthcare delivery in challenging environments. Here’s an overview of what to expect […]

Medical Technology Enterprise Consortium (MTEC) Multi-Topic Request for Proposals Read More »

curative cell therapies_DECIDE-ET_ARPA-H

Decentralized Engineering of Cells Informed by Dynamic Evidence Exploration Topic

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

ARPA-H_DECIDE-ET_Solicitation_DRAFT Overview of Exploration Topic Although Academic Medical Centers (AMCs) have developed many advanced therapies for rare and fatal diseases,  access to AMCs remains limited due to outdated production methods and inadequate quality validation. To enhancing quality assurance technologies at AMCs, the Advanced Research Projects Agency for Health (ARPA-H) has initiated the Decentralized Engineering of

Decentralized Engineering of Cells Informed by Dynamic Evidence Exploration Topic Read More »

in silico modeling for ADME-Tox simulation

Computational ADME-Tox Analysis for Safer Therapeutics (CATALYST) Innovative Solutions Opening

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

CATALYST_ISO_(DRAFT) Overview of CATALYST Solicitation Current in vivo animal model testing methods often fail to predict human drug safety accurately, leading to inefficiencies and high costs. The Health Science Futures (HSF) Office of the Advanced Research projects Agency for Health (ARPA-H) has introduced the CATALYST program to transform drug development. This program will foster the

Computational ADME-Tox Analysis for Safer Therapeutics (CATALYST) Innovative Solutions Opening Read More »

Gene therapy

EverGlade Consulting Helps Cirsium Secure up to $61 Million in ARPA-H Funding

Leave a Comment / ARPA-H, EverGlade Insights / By

EverGlade Consulting, a national consulting firm, has helped Cirsium Biosciences successfully secure up to $61 million in funding to create a rapid, safe, scalable, and low-cost plant-based manufacturing platform to drastically reduce production time and cost of viral vector-based gene therapies. How Funding Will Be Used The $61 million in ARPA-H funding will enable Cirsium

EverGlade Consulting Helps Cirsium Secure up to $61 Million in ARPA-H Funding Read More »

Scroll to Top
A yellow lab flask with Donald Trump hair and a red tie.

Webinar: R&D Funding in Life Sciences: What's Ahead in Trump 2.0?

Join us on Jan 15, 2025, at 12:00pm ET for a deep dive into the future of R&D Funding in Life Sciences.

Sign Up